Lexston Life Sciences Corp. (LEXTF)
USD 0.19
(14.35%)
USD 0.19
(14.35%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -390.4 Thousand CAD | 23.6% |
| 2023 | -510.99 Thousand CAD | 13.46% |
| 2022 | -590.49 Thousand CAD | 37.79% |
| 2021 | -949.17 Thousand CAD | -455.83% |
| 2020 | -170.76 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -233.87 Thousand CAD | 58.93% |
| 2024 Q4 | -390.4 Thousand CAD | -263.53% |
| 2024 Q3 | -107.39 Thousand CAD | 54.08% |
| 2024 Q1 | -569.45 Thousand CAD | -11.44% |
| 2023 Q2 | -994.09 Thousand CAD | 25.25% |
| 2023 Q1 | -1.32 Million CAD | -125.2% |
| 2023 Q4 | -510.99 Thousand CAD | 25.61% |
| 2023 FY | -510.99 Thousand CAD | 13.46% |
| 2023 Q3 | -686.88 Thousand CAD | 30.9% |
| 2022 FY | -590.49 Thousand CAD | 37.79% |
| 2022 Q3 | -782.93 Thousand CAD | 21.04% |
| 2022 Q2 | -991.58 Thousand CAD | -14.0% |
| 2022 Q1 | -869.83 Thousand CAD | 0.0% |
| 2022 Q4 | -590.49 Thousand CAD | 24.58% |
| 2021 Q2 | -751.7 Thousand USD | 0.0% |
| 2021 FY | -949.17 Thousand CAD | -455.83% |
| 2020 FY | -170.76 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 20.27 Million USD | 101.925% |
| Skye Bioscience, Inc. | -5.72 Million USD | 93.176% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 93.808% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -56.4% |
| Qrons Inc. | 351.42 Thousand USD | 211.091% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 108.73% |
| CSL Limited | 10.52 Billion USD | 100.004% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.912% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 106.912% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 161.465% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.899% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -1813.0% |
| Rebus Holdings, Inc. | 305 Thousand USD | 228.002% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -29701.908% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 162.729% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 2065.093% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 102.477% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 109.48% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 197.152% |
| SQZ Biotechnologies Company | -36.23 Million USD | 98.923% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 117.411% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 142.106% |
| Mesoblast Limited | 55.85 Million USD | 100.699% |
| Marizyme, Inc. | 18.56 Million USD | 102.102% |
| Genus plc | 190.6 Million USD | 100.205% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 117.461% |
| Pharming Group N.V. | 109.8 Million USD | 100.356% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 145.383% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 132.162% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 157.413% |
| ContraFect Corporation | -6.02 Million USD | 93.521% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 389.964% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 133.789% |
| IMV Inc. | 7.67 Million USD | 105.09% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 107.096% |
| MultiCell Technologies, Inc. | 90.04 USD | 433690.626% |
| ONE Bio Corp. | 9.04 Million USD | 104.319% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 46.81% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 103.016% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 128.539% |
| Q BioMed Inc. | 4.06 Million USD | 109.616% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 101.278% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 138.742% |
| Biomind Labs Inc. | 711.4 Thousand USD | 154.878% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.645% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 119.526% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 103.048% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 208.533% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 379.252% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 117.73% |
| GB Sciences, Inc. | 1.74 Million USD | 122.343% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -112.421% |
| HST Global, Inc. | 96.79 Thousand USD | 503.34% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 289.318% |
| Halberd Corporation | 144.72 Thousand USD | 369.764% |
| Enzolytics Inc. | 981.65 Thousand USD | 139.77% |
| Agentix Corp. | 37.63 Thousand USD | 1137.456% |
| Resverlogix Corp. | 6.45 Million USD | 106.052% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 41.998% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.981% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 99.17% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 105.521% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 114.413% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 95.584% |
| AVAX Technologies, Inc. | -5.9 Million USD | 93.387% |
| Zenith Capital Corp. | 10.06 Thousand USD | 3979.223% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.963% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 294.782% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 116.362% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 337.315% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -2031.264% |
| Kadimastem Ltd | -253.1 Thousand USD | -54.248% |
| Helix BioMedix, Inc. | -2.57 Million USD | 84.809% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 293.986% |
| LadRx Corporation | -2.03 Million USD | 80.829% |
| Cell Source, Inc. | 9.23 Million USD | 104.229% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 161.465% |
| NovAccess Global Inc. | 2.17 Million USD | 117.921% |
| Affymax, Inc. | -5.59 Million USD | 93.025% |
| Itoco Inc. | 228.3 Thousand USD | 271.002% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 387.086% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 107.876% |
| Mobile Lads Corp. | 484.23 Thousand USD | 180.624% |
| CytoDyn Inc. | 20.26 Million USD | 101.927% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -60240.804% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -4112.243% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 105.066% |
| SYBLEU INC | 473.71 Thousand USD | 182.414% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 108.759% |
| International Stem Cell Corporation | 2.59 Million USD | 115.074% |
| Bioxytran, Inc. | 1.89 Million USD | 120.559% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 725.519% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 117.901% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 111.369% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 104.565% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 150.531% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 68.768% |
| Neutra Corp. | 52.18 Thousand USD | 848.089% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 84.315% |
| PureTech Health plc | -167.19 Million USD | 99.766% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -59.409% |
| IXICO plc | -4.44 Million USD | 91.216% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 102.953% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.712% |
| CSL Limited | 10.52 Billion USD | 100.004% |
| Cellectis S.A. | -43.81 Million USD | 99.109% |